Gilead's Kite exits China cell therapy joint venture with Fosun Pharma
Fierce Pharma
SEPTEMBER 19, 2024
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma.
Let's personalize your content